ClinicalTrials.gg
CompletedNCT06176963Updated Dec 30, 2024Results posted

A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

A Phase 2 interventional study of SB11 PFS in Neovascular Age-related Macular Degeneration, Macular Edema and Retinal Vein Occlusion, sponsored by Samsung Bioepis Co., Ltd.. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
58th of 91
34 · median 50
Started
2023
the only one that year
Phase 2
19 of 91
none open now
Registered
89th of 91
by date

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 58th largest by enrollment, is the only one that started in 2023, is one of 19 in phase 2, and was the 89th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to subjects with nAMD or Macular Oedema Secondary to RVO.

Read the detailed description

This is an open-label, single group, single dose study in subjects with nAMD or Macular Oedema Secondary to RVO.

Screening and Day 1 can be performed on the same day. Subjects will receive ITV injection of SB11 PFS (0.5 mg ranibizumab in 0.05 mL) on Day 1, and follow up visit will be made on Day 1 (+2).

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Macular Edema
  • Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neovascular AMD or macular oedema secondary to RVO in the study eye
  • Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the ophthalmologist (e.g., retina specialist)
  • Aged 18 years and older at the time of signing the form (ICF)
  • Written ICF must be obtained from the subject prior to any study-related procedure (if the subject cannot read ICF, an impartial witness will be present during the entire informed consent discussion)
  • Willingness and ability to undertake all scheduled visits and assessments

Exclusion criteria

Exclusion Criteria:

  • Best Corrected Visual Acuity (BCVA) of the level of Finger Count or worse [i.e., 0 letter reading using Early Treatment Diabetic Retinopathy Study (ETDRS) chart] in one or both eyes at Screening or at Day 1
  • History of and/or current intraocular inflammation (any grading from trace and greater is excluded), including non-infectious uveitis, infectious uveitis, or scleritis, or history of sterile inflammatory reaction after the past ITV injections with any agent in either eye
  • Active or suspected infectious disease, or active disorder that preclude safe use of IP at the discretion of the Investigator, in either eye or adnexa of either eye at Screening or at Day 1
  • History of excessive bleeding and recurrent haemorrhages, including any prior excessive intraocular bleeding or haemorrhages after ITV injection or intraocular procedures in either eye
  • History of massive subconjunctival haemorrhages of concern reported by the subject after an ITV injection in either eye
  • Uncontrolled intraocular pressure (IOP) greater than (≥) 25 mmHg in the study eye at Screening or at Day 1
  • Treatment with any ITV injection within the 30 days prior to Day 1 in the study eye
  • Any invasive ocular surgery including retinal detachment surgery, long-acting ocular therapeutic agent/implant including , or ocular drug release device implant (approved or ) in the study eye within 90 days prior to Day 1 or planned intraocular surgery within next 28 days after Day 1
  • Ocular laser surgery in study eye at any time within the past 30 days prior to Day 1
  • Treatment with any ocular IP in either eye within 90 days prior to Day 1
  • Treatment with systemic anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days prior to Day 1
  • Receipt of any systemic (non-ocular) IP within 180 days prior to Day 1
  • Use of therapies that are known to be toxic to ocular tissue within the 180 days prior to Day 1, including, but not limited to, deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin, or ethambutol
  • Known ocular or non-ocular conditions that per the ophthalmologist (e.g., retina specialist) represent a to ranibizumab use in the patient or may represent an unwarranted patient risk
  • Uncontrolled hypertension (defined as systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg while sitting confirmed after repeated measurement) at Screening or Day 1
  • Current systemic infectious disease or therapy for active infectious disease
  • Pregnant or lactating women at Screening or at Day 1

Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    SB11 PFS

    Subjects received a single dose of SB11 PFS containing 0.5 mg ranibizumab in 0.05 mL solution.

    Combination Product: SB11 PFS

Interventions

  • Combination productSB11 PFS

    SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection

    Also known as: Ranibizumab

06

What researchers measure

Primary outcomes

  1. Percentage of Successful Task Completions

    Total of 12 tasks were evaluated, and the percentage of HCP's successful task completions were measured. Participating HCPs were allotted sufficient time to review the instructions for use (IFU) before preparing and administering the ITV injection on Day 1. HCP participants did not receive any additional training for the SB11 PFS prior to or during the study. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the primary endpoint was the percentage of successful tasks completion among total attempts in this study.

    Time frame: Day 1

Secondary outcomes

  1. Percentage of Successful Completion on Critical Tasks

    Total of 6 tasks were considered as critical task, and the percentage of HCP's successful completion on critical tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful critical tasks (total of 6) completion among total attempts in this study.

    Time frame: Day 1

  2. Percentage of Successful Completion on Essential Tasks

    Total of 6 tasks were considered as essential task, and the percentage of HCP's successful completion on essential tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful essential tasks (total of 6) completion among total attempts in this study.

    Time frame: Day 1

07

Results

Posted Dec 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneSB11 PFS - Subjects
Started34
Completed34
Not completed0

Outcome measures

PrimaryPercentage of Successful Task Completions

Total of 12 tasks were evaluated, and the percentage of HCP's successful task completions were measured. Participating HCPs were allotted sufficient time to review the instructions for use (IFU) before preparing and administering the ITV injection on Day 1. HCP participants did not receive any additional training for the SB11 PFS prior to or during the study. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the primary endpoint was the percentage of successful tasks completion among total attempts in this study.

Time frame:
Day 1
Reported as:
Number · Percentage of successful task completion
Percentage of Successful Task Completions
Percentage of successful task completionSB11 PFS
Open the carton100
Remove contents100
Peel the lid off the blister pack100
Carefully remove the PFS from the blister using aseptic technique100
Remove the syringe cap100
Attach a needle100
Remove the needle cap100
Set the dose100
Insert the needle into the injection site100
Press the plunger down to inject the medication100
Remove the needle from the injection site100
Dispose product100
SecondaryPercentage of Successful Completion on Critical Tasks

Total of 6 tasks were considered as critical task, and the percentage of HCP's successful completion on critical tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful critical tasks (total of 6) completion among total attempts in this study.

Time frame:
Day 1
Reported as:
Number · Percentage of successful task completion
Percentage of Successful Completion on Critical Tasks
Percentage of successful task completionSB11 PFS
Percentage of Successful Completion on Critical Tasks100
SecondaryPercentage of Successful Completion on Essential Tasks

Total of 6 tasks were considered as essential task, and the percentage of HCP's successful completion on essential tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful essential tasks (total of 6) completion among total attempts in this study.

Time frame:
Day 1
Reported as:
Number · Percentage of successful task completion
Percentage of Successful Completion on Essential Tasks
Percentage of successful task completionSB11 PFS
Percentage of Successful Completion on Essential Tasks100

Adverse events

Collected over Overall Period (Day 7). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SB11 PFS0/34 (0%)0/34 (0%)2/34 (5.9%)
Most frequent other events
Most frequent other events
EventSB11 PFS
Ocular discomfortEye disorders1/34
Ocular hyperaemiaEye disorders1/34
NasopharyngitisInfections and infestations1/34

Baseline characteristics

34 subjects were enrolled in the study.

Age, Continuous
Age, Continuous(years)SB11 PFS
Mean74.1 ± 7.45
Sex: Female, Male
Sex: Female, Male(Participants)SB11 PFS
Female21
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SB11 PFS
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White34
More than one race0
Unknown or Not Reported0
Main Indication
Main Indication(Participants)SB11 PFS
Neovascular AMD32
Macular Oedema Secondary to RVO2
08

Study locations

3 sites
  • SB Investigational Site
    Katowice, Poland
  • SB Investigational Site
    Kraków, Poland
  • SB Investigational Site
    Olsztyn, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2023, 0 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 0 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 20, 2023
StartActual
Nov 21, 2023
Primary completionActual
Nov 30, 2023
CompletionActual
Dec 12, 2023
Results first posted
Dec 30, 2024
Last update
Dec 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06176963
Responsible party
Sponsor
First posted
Dec 20, 2023
Start date
Nov 21, 2023
Primary completion
Nov 30, 2023
Completion
Dec 12, 2023
Results posted
Dec 30, 2024
Last update
Dec 30, 2024

Study contacts

Piotr Oleksy, M.D.
principal investigator · Centrum Medyczne Dietla 19 Krakow

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion